U.S. Patent and Trademark Office has granted to Todos Medical two additional patents

REHOVOT, Israel, Feb. 12, 2018 -- Todos Medical, Ltd. Inc. (OTCQB:TOMDF) (www.todosmedical.com), a clinical-stage in-vitro diagnostics company focused on the development of blood tests for the early detection of cancer, announced today that the U.S. Patent and Trademark Office has granted to Todos Medical two patents for broader claims for its inventions. 

The first patent is titled, Biochemical Analysis of PBMCs (US 9,606,057 B2). The patent relates to analysis of an infrared (“IR”) spectrum of a peripheral blood mononuclear cells (“PBMC”) sample to indicate the presence of a solid tumor in breast tissue.

The second patent is titled, Infrared Analysis of Benign Tumors (US 9,804,145 B2). The patent covers Todos Medical’s innovative TBIA (Total Biochemical Infrared Analysis) technology applied to differentiate between benign and malignant tumors. This is an application regarding (i) analysis of an IR spectrum of a PBMC sample to indicate the presence of a benign tumor in breast tissue and in the gastrointestinal tract, and (ii) analysis of an IR spectrum of a blood plasma sample to indicate the presence of a benign tumor. The Company believes that this patent is an important milestone in protecting the Company’s technology and in strengthening the Company’s position as a leader in its field. 

The above-mentioned patents are in addition to the original patent that the Company received on August 1, 2017 (patent 9,719,937 B2). That patent relates to analysis of an IR spectrum of a blood plasma sample to indicate the presence of a solid tumor in the gastrointestinal tract.

“Obtaining these patents demonstrates our innovative approach to cancer screening and protects the intellectual property of Todos Medical as we continue to work diligently on clinical trials with our ultimate goal of bringing our cancer screening tests to market,” said Rami Zigdon, CEO of Todos Medical.

About Todos Medical

Todos Medical Ltd. (OTCQB:TOMDF) an Israeli company headquartered in Rehovot, is a cancer in-vitro-diagnostic (“IVD”) company engaging in the development of a series of blood tests for the early detection of a variety of cancers. The company has developed two cancer screening tests based on TBIA (Todos Biochemical Infrared Analyses), a method for cancer screening using peripheral blood analysis. The TBIA screening method is based on the cancer’s influence on the immune system which triggers biochemical changes in peripheral blood mononuclear cells (“PBMC”) and plasma. This proprietary and patented method incorporates biochemistry, physics and signal processing. The company’s two cancer screening tests, TM-B1 and TM-B2 are CE marked in the EU.

For more information, the content of which is not part of this press release, please visit http://www.Todosmedical.com .

Forward-looking statements: This press release contains forward-looking statements. For example, we are using forward-looking statements when we discuss our expected clinical development programs and clinical trials. These forward-looking statements are only based on the current expectations of the management of Todos Medical, and are subject to a number of factors and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements, including the risks and uncertainties related to the progress, timing, cost, and results of clinical trials and product development programs; difficulties or delays in obtaining regulatory approval or patent protection for our product candidates; competition from other biotechnology companies; and our ability to obtain additional funding required to conduct our research, development and commercialization activities. In addition, the following factors, among others, could cause actual results to differ materially from those described in the forward-looking statements: changes in technology and market requirements; delays or obstacles in launching our clinical trials; changes in legislation; inability to timely develop and introduce new technologies, products and applications; lack of validation of our technology as we progress further and lack of acceptance of our methods by the scientific community; inability to retain or attract key employees whose knowledge is essential to the development of our products; unforeseen scientific difficulties that may develop with our process; greater cost of final product than anticipated; loss of market share and pressure on pricing resulting from competition; and laboratory results that do not translate to equally good results in real settings, all of which could cause the actual results or performance of Todos Medical to differ materially from those contemplated in such forward-looking statements. Except as otherwise required by law, Todos Medical undertakes no obligation to publicly release any revisions to these forward-looking statements to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. For a more detailed description of the risks and uncertainties affecting Todos Medical, reference is made to Todos Medical’s reports filed from time to time with the U.S. Securities and Exchange Commission.

Media Contact:

Todos Medical Ltd.
Daniel Hirsch
Investor Relations
[email protected]
(347) 699-0029